key: cord-0747110-66kaybd2
authors: Lohse, Anne; Klopfenstein, Timothée; Balblanc, Jean-Charles; Royer, Pierre-Yves; Bossert, Marie; Gendrin, Vincent; Charpentier, Aline; Bozgan, Ana-Maria; Badie, Julio; Bourgoin, Charlotte; Contreras, Remy; Mazurier, Isabelle; Conrozier, Thierry; Zayet, Souheil
title: Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19)
date: 2020-06-20
journal: Microbes Infect
DOI: 10.1016/j.micinf.2020.06.005
sha: 0d5b4b876357c050c7716a1c8c2456306c90aaf3
doc_id: 747110
cord_uid: 66kaybd2

COVID-19 patients (n=34) suffering from ARDS were treated with tocilizumab (TCZ). Outcome was classified in two groups: “Death” and “Recovery”. Predictive factors of mortality were studied. Mean age was 75.3, mean oxygen (O(2)) requirements 10.4 l/min. At baseline, all patients had multiple biological abnormalities (lymphopenia, increased CRP, ferritin, fibrinogen, D-dimer and liver enzymes). 24 patients (70.5%) recovered after TCZ therapy and 10 died (29.5%). Deceased subjects differed from patients in whom treatment was effective with regard to more pronounced lymphopenia (0.6 vs 1.0 G/l; p=0.037), lower platelet number (156 vs 314 G/l; p=0.0001), lower fibrinogen serum level (0.6 vs 1.0 G/l; p=0.03), higher aspartate-amino-transferase (108 vs 57 UI/l; p=0.05) and greater O(2) requirements (11 vs 8 l/min; p= 0.003).

The outbreak of coronavirus disease 2019 (1) due to SARS-CoV-2 (Severe Acute 42 Respiratory Syndrome Coronavirus 2) has left behind tens of thousands deaths worldwide, in 43 only a few months. On March 11 th , 2020, COVID-19 outbreak was declared a pandemic by the 44 World Health Organization (1). Data from China, the cradle of the pandemic, pointed out that 45 older and frail patients may develop severe disease with respiratory distress and multi-organ 46 failure, resulting in death in about 4% of the cases (2). Acute respiratory distress syndrome 47 (ARDS) related to SARS-CoV-2 is likely due to a cytokine dysregulation, occurring during the 48 second week of the disease. This cytokine "storm" is characterized by a major release of pro-49 inflammatory cytokines, including interleukine-6 (IL-6), IL-2, IL-7, IL-10, granulocyte-colony- 50 stimulating factor (G-CSF), interferon γ inducible protein (IP10) and tumor necrosis factorα (2-4). 51 Blocking this excessive cytokine production might be the key of the COVID-19-ARDS treatment. 52 Elevated IL-6 levels, correlated with clinical severity, were found in patients with other cytokine 53 release syndrome (CRS) (5). Remarkable beneficial effects of IL-6 blockade therapy using a 54 humanized anti-IL-6 receptor antibody, tocilizumab (TCZ) were observed in patients with CRS 55 due to chimeric antigen receptor T-cell therapy (6). Many reports underlined the major interest 56 of TCZ, and other cytokine blockade, in the treatment of the COVID-19 related CRS (2, 4, (7) (8) (9) (10) (11) (12) (13) (14) (15) . 57 Due to increasing evidence that TCZ might reduce mortality in patients with COVID-19 related 58 CRS, a scientific committee was constituted within the Nord Franche-Comté (NFC) Hospital on 59 the very last days of March 2020. The committee, including infectious diseases specialists, 60 rheumatologists, pharmacists and intensivists, proposed to authorize the off-label use of TCZ in 61 patients who were developing ARDS with rapid increase of O 2 requirements (i.e. exceeding 5 62 liter / minute with high concentration mask), after failure of a treatment including 63 hydroxychloroquine and/or IV corticosteroids, still within the window of opportunity for TCZ 64 treatment (day 7 to day 17 after onset of symptoms). To be eligible for TCZ therapy each case 65 had to be discussed during a daily multidisciplinary consultation meeting (MCM) including 66 infectious diseases specialists rheumatologist, pharmacists, biologists and intensivists. Between 67 April 1 st and May 11 th , 2020, 40 severe COVID-19 patients were treated with TCZ in our hospital. 68 Contraindications for TCZ were bacterial superinfection, latent tuberculosis infection, 69 macrophage activation syndrome and hypersensitivity to tocilizumab. 70 We have recently published a retrospective case-control study on our first sample of patients 71 treated with TCZ (16). Despite a Charlson comorbidity index higher than that of patients from 72 the control group, more severe disease, higher oxygen requirement and poorer biological 73 findings, patients treated with TCZ had a better prognosis than control with a death rate of 25% 74 and 48% respectively. However the percentage of deceased patients remains rather high and 75 justifies looking for the reasons of the treatment failure in about 1 patient out of 4. 76 The aim of the present work was to identify prognostic factors of mortality in subjects treated 77 with TCZ for COVID-19 severe pneumonia, in order to better select further patients, and (i.e. amoxicillin/clavulanic acid or cefotaxime or levofloxacin), hydroxychloroquine (800 mg/day 92 at day 1, then 400 mg/day from day 2 to day 10), enoxaparin at anticoagulant dose and 93 paracetamol (1 to 3 g/d). Some of them received IV methylprednisolone at a dosing regimen of 94 0.5 to 2 mg/kg/day, 1 to 5 consecutive days. 95 All patients received oxygen therapy, using high concentration mask. The oxygen flow was 96 calculated to obtain oxygen saturation between 92 and 96%. Oxygen saturation was measured 97 every 4 hours using a digital saturometer. 

The following data were collected from the patients' medical file: demographic characteristics 101 (age, gender, height, weight, body mass index), comorbidities, concomitant treatments for 102 comorbidities, previous and current treatments for COVID-19, clinical characteristics, oxygen 103 requirements, oxygen saturation, lung CT-scan lesions and biological data, before TCZ treatment. 104 In all patients admitted in the NFC Hospital for COVID-19, regardless the severity of the disease, 105 the laboratory tests at entry included blood count, blood electrolytes, glycaemia, creatinine and 106 clearance, C reactive protein (CRP), bilirubin, aspartate aminotransferase (AST), alanine 107 aminotransferase (ALT), alkaline phosphatases, gamma glutamyltransferase, ferritin, fibrinogen, 108 D-dimer, prothrombin, triglycerides, lactate dehydrogenase (LDH), creatin kinase (CK) and 109 arterial blood PO 2 and PCO 2 . The same blood tests were repeated every 2 or 3 days until 110 patients got out of the hospital.

Lung CT-scan was performed to confirm diagnosis and to assess pneumonia severity by 112 measuring the extent of the lung lesions (especially plaque-like and ground-glass opacities. 113 condensation. crazy paving). Extent was classified <10%, 10-25%, 25-50%. 50-75% or >75%. 114 Diagnosis of COVID-19 had to be proven by real-time RT-PCR on respiratory samples, mainly 115 nasopharyngeal swabs, sputum and bronchial aspirates. Briefly, viral RNA was extracted using 116 the NucleoSpin ® RNA Virus kit (Macherey-Nagel) according to the manufacturers' instructions, 117 and amplified by RT-PCR protocols developed by the Charité (E gene) (17) (Table II) . There was a trend for older age (80 vs 73.1 years; p=0.11) that did In summary, our short single-center experience encourages us to continue treating with TCZ 212 patients suffering from SARS-CoV-2 severe pneumonia. In patients with COVID-19-ARDS, whose 213 life was threatened, treatment with TCZ resulted in favorable evolution in 70% of the cases. 214 However, older patients with higher O 2 needs, more severe lymphopenia, lower fibrinogen and 215 higher AST levels were less likely to benefit from TCZ. Further larger scale prospective trials are 216 mandatory to conclude with certainty on the best patient profile and the right time to initiate 217 the treatment. 

First case of COVID-19 in a 287 patient with multiple myeloma successfully treated with tocilizumab

COVID-291 19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD

Clinical course and risk factors for 315 mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort 316 study

Clinical course and mortality risk of severe COVID-19

Risk factors of critical & mortal 321

COVID-19 cases: A systematic literature review and meta-analysis

Predictors of response and remission in a large cohort of rheumatoid arthritis patients 326 treated with tocilizumab in clinical practice